Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 3/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.37 |
| ▸ | PPARG | P37231 | 7/20 | 0.37 |
| ▸ | PPARD | Q03181 | 7/20 | 0.37 |
| ▸ | PPARA | Q07869 | 7/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21048580 | 1.00 | KDM5A (0.37) | KDM5APHF8KDM4CGPR84PPARG | |
| SCHEMBL4334125 | 1.00 | KDM5A (0.37) | KDM5APHF8KDM4CGPR84PPARG | |
| Hydrochloric Acid SCHEMBL4290887 | 0.99 | KDM5A (0.36) | KDM5APHF8KDM4CGPR84PPARG | |
| Hydrochloric Acid SCHEMBL9330621 | 0.99 | KDM5A (0.36) | KDM5APHF8KDM4CGPR84PPARG | |
| Hydrochloric Acid SCHEMBL345724 | 0.99 | KDM5A (0.36) | KDM5APHF8KDM4CGPR84PPARG | |
| Hydrochloric Acid SCHEMBL4293179 | 0.99 | KDM5A (0.36) | KDM5APHF8KDM4CGPR84PPARG | |
| Hydrochloric Acid SCHEMBL4302158 | 0.92 | EPHX2 (0.47) | PPARGPPARDPPARAPTPN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15948948 | 0.92 | EPHX2 (0.47) | PPARGPPARDPPARAPTPN1ALDH1A1 | |
| SCHEMBL4325883 | 0.90 | KDM5A (0.36) | KDM5APHF8KDM4CGPR84PPARG | |
| SCHEMBL4334127 | 0.90 | KDM5A (0.36) | KDM5APHF8KDM4CGPR84PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035723-A1 | Treatment of Pancreatic Cancer | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2023-02-02 | — | — | US | claimed |
| US-20220313608-A1 | TREATMENT OF BREAST CANCER | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2022-10-06 | — | — | US | claimed |
| EP-3397244-B1 | TREATMENT OF BREAST CANCER USING A COMBINATION OF A CATIONIC LIPOSOMAL FORMULATION OF TAXANE, A NON-LIPOSOMAL FORMULATION OF TAXANE AND A FURTHER ACTIVE AGENT | SYNCORE BIOTECHNOLOGY CO LTD (TW) | 2021-10-06 | — | — | EP | claimed |
| EP-1385933-B1 | CULTURE MEDIUM FOR CELL GROWTH AND TRANSFECTION | LIFE TECHNOLOGIES CORP (US) | 2012-07-11 | — | — | EP | claimed |
| EP-0475178-B1 | Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation | VITAMIN KENKYUSHO KK (JP) | 1994-03-30 | — | — | EP | claimed |
| JP-9248182-A | — | — | None | — | — | JP | disclosed |
| US-20260146070-A1 | FUNCTIONALLY MODIFIED MAYTANSINOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260124210-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S) | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260091038-A1 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | MASSACHUSETTS INST TECHNOLOGY (US) | 2026-04-02 | — | — | US | disclosed |
| US-12582658-B2 | Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s) | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | UNIV GEORGIA (US) | 2026-03-12 | — | — | US | disclosed |
| EP-2034019-A1 | COMPOSITION FOR NUCLEIC-ACID INTRODUCTION | Hokkaido System Science Co., Ltd. (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20090022782-A1 | Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue | NATIONAL UNIVERSITY CORP. HOKKAIDO UNIVERSITY (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1862470-A1 | ELEMENT RETAINED IN BLOOD SHOWING DEGRADABILITY SELECTIVELY IN TUMOR TISSUE | National University Corporation Hokkaido University (JP) | 2007-12-05 | — | — | EP | disclosed |
| US-20070112176-A1 | Lipid membrane structure containing anti-mt-mmp monoclonal antibody | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1618897-A1 | LIPID MEMBRANE STRUCTURE CONTAINING ANTI-MT-MMP MONOCLONAL ANTIBODY | The University of Tokyo (JP) | 2006-01-25 | — | — | EP | disclosed |
| CN-1506041-A | Formulation and making process of genetic skin beautifying and whitening cosmetics | 殷冬生 | 2004-06-23 | — | — | CN | disclosed |
| CN-1427008-A | Method of designing and selecting natural siRNA as gene medicine and medicine formulation | YIN DONGSHENG (CN) | 2003-07-02 | — | — | CN | disclosed |
| JP-H09248182-A | MULTILAMELLAR LIPOSOME FOR EMBEDDING PLASMID THEREIN | OYO SEIKAGAKU KENKYUSHO | 1997-09-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091038-A1 | COMPOSITIONS AND METHODS FOR ENHANCING WNT SIGNALING FOR TREATING CANCER | WNT3A, APC, WNT3 | KDM5A 2866/4885PHF8 4450/4885KDM4C 3148/4885 |
| US-12582658-B2 | Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s) | PLK1, BUB1, WEE1 | KDM5A 3724/4885PHF8 2559/4885KDM4C 3299/4885 |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | APOL1, APOB, LY96 | KDM5A 4527/4885PHF8 3392/4885KDM4C 4624/4885 |
| US-20260146070-A1 | FUNCTIONALLY MODIFIED MAYTANSINOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF | NOS1, NOS3, NOX5 | KDM5A 308/4885PHF8 1760/4885KDM4C 659/4885 |
| US-20260124210-A1 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S) | PLK1, BUB1, BUB1B | KDM5A 3763/4885PHF8 2787/4885KDM4C 3379/4885 |
| US-12605470-B2 | Nanodroplet with layer-by-layer assembly | FLNB, FLNA, DAGLB | KDM5A 3962/4885PHF8 3910/4885KDM4C 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.